The rationale behind the Forsvall Needle

Reduced bacterial transfer by 96%*

About 3% of patients in transrectal and 1% of transperineal biopsies suffer an infection. Infections are caused by bacterial transfer. The Forsvall needle reduces bacterial transfer by 96%*. Clinical trials are planned to evaluate the effect on clinical infections.

On target technology by addressing deviation

A clinical problem is needle deviation away from the tumour, impairing the urologist's hit rate and downstream cancer diagnostics. The Forsvall needle is built to reduce deviation. Clinical trials are planned to evaluate the effect on cancer diagnostics.